182 related articles for article (PubMed ID: 17717432)
1. Diagnostic uses of Pax5 immunohistochemistry.
Feldman AL; Dogan A
Adv Anat Pathol; 2007 Sep; 14(5):323-34. PubMed ID: 17717432
[TBL] [Abstract][Full Text] [Related]
2. PAX immunoreactivity identifies alveolar rhabdomyosarcoma.
Sullivan LM; Atkins KA; LeGallo RD
Am J Surg Pathol; 2009 May; 33(5):775-80. PubMed ID: 19145202
[TBL] [Abstract][Full Text] [Related]
3. Pax5 expression in non-Hodgkin's lymphomas and acute leukemias.
Zhang X; Lin Z; Kim I
J Korean Med Sci; 2003 Dec; 18(6):804-8. PubMed ID: 14676435
[TBL] [Abstract][Full Text] [Related]
4. PAX8 and PAX5 are differentially expressed in B-cell and T-cell lymphomas.
Morgan EA; Pozdnyakova O; Nascimento AF; Hirsch MS
Histopathology; 2013 Feb; 62(3):406-13. PubMed ID: 23163626
[TBL] [Abstract][Full Text] [Related]
5. Biphenotypic bigenotypic lymphoma with simultaneous expression of PAX5/BSAP and B- and T-cell markers.
Hansson M; Jerkeman M; Dictor M
Eur J Haematol; 2007 Aug; 79(2):159-65. PubMed ID: 17635241
[TBL] [Abstract][Full Text] [Related]
6. Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: a novel canine pan pre-B- and B-cell marker.
Willmann M; Müllauer L; Guija de Arespacochaga A; Reifinger M; Mosberger I; Thalhammer JG
Vet Immunol Immunopathol; 2009 Apr; 128(4):359-65. PubMed ID: 19100628
[TBL] [Abstract][Full Text] [Related]
7. Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators.
Cho RJ; McCalmont TH; Ai WZ; Fox LP; Treseler P; Pincus LB
J Cutan Pathol; 2012 Jun; 39(6):651-8. PubMed ID: 22324490
[TBL] [Abstract][Full Text] [Related]
8. B-cell specific activation protein encoded by the PAX-5 gene is commonly expressed in merkel cell carcinoma and small cell carcinomas.
Dong HY; Liu W; Cohen P; Mahle CE; Zhang W
Am J Surg Pathol; 2005 May; 29(5):687-92. PubMed ID: 15832095
[TBL] [Abstract][Full Text] [Related]
9. Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
Mhawech-Fauceglia P; Saxena R; Zhang S; Terracciano L; Sauter G; Chadhuri A; Herrmann FR; Penetrante R
J Clin Pathol; 2007 Jun; 60(6):709-14. PubMed ID: 16837628
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms.
Adams H; Liebisch P; Schmid P; Dirnhofer S; Tzankov A
Appl Immunohistochem Mol Morphol; 2009 Mar; 17(2):96-101. PubMed ID: 18838917
[TBL] [Abstract][Full Text] [Related]
11. Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-cells.
Arseneau JR; Laflamme M; Lewis SM; Maïcas E; Ouellette RJ
Br J Haematol; 2009 Nov; 147(3):328-38. PubMed ID: 19725825
[TBL] [Abstract][Full Text] [Related]
12. PAX-5 is invariably expressed in B-cell lymphomas without plasma cell differentiation.
Dong HY; Browne P; Liu Z; Gangi M
Histopathology; 2008 Sep; 53(3):278-87. PubMed ID: 18643853
[TBL] [Abstract][Full Text] [Related]
13. Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker.
Nasr MR; Rosenthal N; Syrbu S
Am J Clin Pathol; 2010 Jan; 133(1):41-8. PubMed ID: 20023257
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Pax5 expression and comparison with BLA.36 and CD79αcy in feline non-Hodgkin lymphoma.
Felisberto R; Matos J; Alves M; Cabeçadas J; Henriques J
Vet Comp Oncol; 2017 Dec; 15(4):1257-1268. PubMed ID: 27549353
[TBL] [Abstract][Full Text] [Related]
15. B-cell transcription factors Pax-5, Oct-2, BOB.1, Bcl-6, and MUM1 are useful markers for the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma.
Herbeck R; Teodorescu Brînzeu D; Giubelan M; Lazăr E; Dema A; Ioniţă H
Rom J Morphol Embryol; 2011; 52(1):69-74. PubMed ID: 21424034
[TBL] [Abstract][Full Text] [Related]
16. Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma.
Khan MR; Ahmad A; Kayani N; Minhas K
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3463-3466. PubMed ID: 30583670
[TBL] [Abstract][Full Text] [Related]
17. CD20 negative primary diffuse large B cell lymphoma of breast: Role of Pax-5.
Shukla S; Awasthi NP; Singh P; Husain N
J Cancer Res Ther; 2015; 11(3):658. PubMed ID: 26458662
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples.
Agostinelli C; Sabattini E; Gjørret JO; Righi S; Rossi M; Mancini M; Piccaluga PP; Bacci F; Marafioti T; Bettini G; Falini B; Pileri SA
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):561-72. PubMed ID: 20697266
[TBL] [Abstract][Full Text] [Related]
19. [Expression of B cell-specific activator protein in lymphomas].
Li D; Li GD; Liu WP; Li FY; Zhang WY; Liao DY
Zhonghua Bing Li Xue Za Zhi; 2005 Jun; 34(6):345-7. PubMed ID: 16185503
[TBL] [Abstract][Full Text] [Related]
20. B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.
Cozma D; Yu D; Hodawadekar S; Azvolinsky A; Grande S; Tobias JW; Metzgar MH; Paterson J; Erikson J; Marafioti T; Monroe JG; Atchison ML; Thomas-Tikhonenko A
J Clin Invest; 2007 Sep; 117(9):2602-10. PubMed ID: 17717600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
